Sage Therapeutics Inc. Stock
Price
Target price
€9.82
€9.82
1.000%
0.098
1.000%
€26.21
04.07.24 / Tradegate
WKN: A117WF / Symbol: SAGE / Name: SAGE / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Sage Therapeutics Inc. Stock
Sage Therapeutics Inc. gained 1.000% compared to yesterday.
Our community is currently high on Sage Therapeutics Inc. with 7 Buy predictions and 4 Sell predictions.
Based on the current price of 9.82 € the target price of 26 € shows a potential of 164.87% for Sage Therapeutics Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Sage Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.
Pros and Cons of Sage Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sage Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc. | 1.000% | -1.761% | -0.808% | -77.792% | -50.920% | -79.374% | - |
| Ironwood Pharmaceuticals | -2.610% | -2.609% | -5.882% | -41.969% | -45.098% | -47.664% | - |
| Novocure Ltd | -0.260% | -6.041% | -27.279% | -59.711% | 8.406% | -90.124% | - |
| Iovance Biotherapeutics Inc. | -1.970% | -10.329% | -12.255% | 2.981% | -14.165% | -69.946% | - |
Comments
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at JPMorgan Chase & Co. from $28.00 to $23.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) is now covered by analysts at Citigroup Inc.. They set a "sell" rating and a $8.00 price target on the stock.
Show more
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $28.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for SAGE provided by MarketBeat